Amneal Pharmaceuticals Inc [AMRX] stock is trading at $7.75, up 0.78%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AMRX shares have lost -2.15% over the last week, with a monthly amount drifted -8.18%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Amneal Pharmaceuticals Inc [NASDAQ: AMRX] stock has seen the most recent analyst activity on September 06, 2024, when JP Morgan upgraded its rating to a Neutral but kept the price target unchanged to $9 for it. On March 08, 2021, upgrade upgraded it’s rating to Buy and revised its price target to $6.50 on the stock. Guggenheim upgraded its rating to a Buy but stick to its price target of $5.50 on December 14, 2020. Barclays upgraded its rating to a Overweight and raised its price target to $6 on December 14, 2020. Goldman started tracking with a Sell rating for this stock on July 27, 2020, and assigned it a price target of $4. In a note dated May 12, 2020, Guggenheim upgraded an Neutral rating on this stock.
Amneal Pharmaceuticals Inc [AMRX] stock has fluctuated between $5.01 and $9.48 over the past year. Currently, Wall Street analysts expect the stock to reach $11.5 within the next 12 months. Amneal Pharmaceuticals Inc [NASDAQ: AMRX] shares were valued at $7.75 at the most recent close of the market. An investor can expect a potential return of 48.39% based on the average AMRX price forecast.
Analyzing the AMRX fundamentals
Amneal Pharmaceuticals Inc [NASDAQ:AMRX] reported sales of 2.68B for the trailing twelve months, which represents a growth of 13.29%. Gross Profit Margin for this corporation currently stands at 0.35% with Operating Profit Margin at 0.07%, Pretax Profit Margin comes in at -0.05%, and Net Profit Margin reading is -0.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is 3.79 and Total Capital is 0.08. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-27.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.65 points at the first support level, and at 7.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.83, and for the 2nd resistance point, it is at 7.92.
Ratios To Look Out For
For context, Amneal Pharmaceuticals Inc’s Current Ratio is 1.38. In addition, the Quick Ratio stands at 0.84 and the Cash Ratio stands at 0.07. Considering the valuation of this stock, the price to sales ratio is 0.90.
Transactions by insiders
Recent insider trading involved Kiely John, Director, that happened on Nov 22 ’24 when 17058.0 shares were sold. Director, Autor Deborah M. completed a deal on Nov 22 ’24 to sell 33229.0 shares. Meanwhile, Director Autor Deborah M. sold 6771.0 shares on Nov 21 ’24.
